The emergence of antimicrobial resistance is one of the most serious health threats to our entire population. Infections from resistant bacteria are now too common, and some pathogens have become resistant to multiple antibiotic classes. The Centers for Disease Control and Prevention (CDC) recently estimated that drug-resistant bacteria account for more than 2 million illnesses and over 23,000 deaths every year in the U.S. With rising rates of drug-resistant infections, there is pressing need for new diagnostic methods that can rapidly determine the most effective therapy for an infection. Unfortunately, the current method for performing antibiotic susceptibility testing (AST) involves growing microorganisms from clinical samples and determining their sensitivity to antibiotics through cell growth. This ?gold standard? technique is extremely time-consuming (minimum 48-72 hours) and can result in significant delays in appropriate therapy, prolonged illness, greater risk of death, inappropriate antibiotic use, and increased spread of resistance. For some infections like gonorrhea, AST is not even performed in the clinic and instead inferred based on treatment failure. In short, it is imperative that new strategies are developed to rapidly diagnose and prevent the amplification of drug resistance. Antibiotic exposure can trigger the expression of a signature set of mRNAs in susceptible microbes in as rapidly as a few minutes, raising the exciting possibility of using RNA detection ? not cell growth ? as a new means for rapid, phenotype-based AST. We will develop innovative RNA sensor technology that evaluates these molecular signatures within a clinically-relevant, low-cost, and easy-to-use diagnostic platform. To achieve this, we will use synthetic biology approaches to engineer highly-sensitive genetic sensors of mRNA. These sensors will be deployed in cell-free expression systems that can be arrayed and freeze-dried onto low-cost, solid-state substrates like paper. The result will be a new class of antibiotic diagnostics with ideal performance, storage, and distribution characteristics. The RNA sensor technology will be developed and validated with high priority bacterial organisms. Notably, we will, for the first time, define RNA signatures of susceptibility for N. gonorrhoeae, which the CDC recently elevated as a major cause for concern in the U.S. and for which AST capabilities do not currently existing in the clinical setting. This work will usher in a new technology for rapidly diagnosing antibiotic resistance, with the potential to transform the management of today's growing antimicrobial resistance problem.
The improper and excessive use of antibiotics in the past decades has led to an alarming increase in antimicrobial resistance. With rising rates of drug-resistant infections, there is pressing need for new diagnostic methods that can rapidly determine the most effective therapy for an infection. We are developing a novel diagnostic system based on rapid molecular sensor technologies to determine antibiotic susceptibilities of bacterial infections.
|Weinstein, Zohar B; Kuru, Nurdan; Kiriakov, Szilvia et al. (2018) Modeling the impact of drug interactions on therapeutic selectivity. Nat Commun 9:3452|
|Krakowiak, Joanna; Zheng, Xu; Patel, Nikit et al. (2018) Hsf1 and Hsp70 constitute a two-component feedback loop that regulates the yeast heat shock response. Elife 7:|
|Wong, Brandon G; Mancuso, Christopher P; Kiriakov, Szilvia et al. (2018) Precise, automated control of conditions for high-throughput growth of yeast and bacteria with eVOLVER. Nat Biotechnol 36:614-623|
|Zheng, Xu; Beyzavi, Ali; Krakowiak, Joanna et al. (2018) Hsf1 Phosphorylation Generates Cell-to-Cell Variation in Hsp90 Levels and Promotes Phenotypic Plasticity. Cell Rep 22:3099-3106|
|Newby, Gregory A; Kiriakov, Szilvia; Hallacli, Erinc et al. (2017) A Genetic Tool to Track Protein Aggregates and Control Prion Inheritance. Cell 171:966-979.e18|